Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Astrana Health (ASTH)

Astrana Health shareholders approve 2024 equity plan with 2 million more shares

Neutral Impact 2 of 5 shareholder Written later

At its June 11, 2025 annual meeting, Astrana Health stockholders approved an amended and restated 2024 Equity Incentive Plan that adds 2,000,000 shares to the reserve and extends the plan's term to March 25, 2035. Stockholders also elected nine directors, ratified Ernst & Young LLP as auditor for fiscal 2025, and approved executive pay on an advisory basis.

Key points

  • Equity plan: 36,772,471 votes for and 1,245,886 against, with 155,856 abstentions; the plan's term now runs to March 25, 2035
  • Directors: all nine nominees were elected to serve until the 2026 annual meeting; Weili Dai received 18,977,644 votes for and 19,196,569 withheld
  • Auditor: Ernst & Young LLP was ratified for the year ending December 31, 2025, with 42,631,420 votes for and 260,880 against
  • Executive pay: the advisory say-on-pay proposal passed with 34,713,926 votes for and 3,370,998 against

The filing

CompanyAstrana Health (ASTH)
Form8-K, current report
Filed with the SECJun 11, 2025, 4:15 PM ET
Accession number0001104659-25-058542

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:54 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 11, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.